M.V. Pilepich - Concepedia

Author

M.V. Pilepich

Also Known As

M Pilepich, M V Pilepich, M. Pilepich, M. V. Pilepich, M.V Pilepich, M.V. Pilepich, Michael Pilepich, Michael V Pilepich, Michael V. Pilepich

Publications

985

Citations

H-Index

Concepts

All Affiliations

RTOG Foundation Fox Chase Cancer Center University of California, San Francisco LDS Hospital University of Pennsylvania

About

M.V. Pilepich is an author at RTOG Foundation specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	649
2	Radiation Medicine	4	4	397
3	Health Sciences	2	2	65
4	Obstetrics	1	1	28
5	Pathology	1	1	31

M.V. Pilepich

Publications

923

Citations

H-Index

Page 1

	Year	Citations
Randomized phase III study comparing best supportive care to biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation therapy oncology group (RTOG) 97-13 James N. Fisher, Charles Scott, Randy E. Stevens, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineOncologyRadiation TherapyBreast IrradiationRadiation Effect	2000	288
p53 Status and Prognosis of Locally Advanced Prostatic Adenocarcinoma: a Study Based on RTOG 8610 David J. Grignon, F. H. Sarkar, J.D. Forman, JNCI Journal of the National Cancer Institute	1997	184
Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10 William U. Shipley, Jiandong Lu, M.V. Pilepich, International Journal of Radiation OncologyBiologyPhysics UrologyProtocol RtogMedicineProstate Cancer PatientsNeoadjuvant Hormonal Therapy	2002	60
MDM2 as a predictor of prostate carcinoma outcome Li‐Yan Khor, Michelle DeSilvio, Tahseen Al‐Saleem, Cancer	2005	58
Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10 William U. Shipley, Michelle DeSilvio, M.V. Pilepich, International Journal of Radiation OncologyBiologyPhysics Rtog ProtocolRadiation MedicineUrologyRadiation TherapyMedicine	2006	48
Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10) André Konski, Eric J. Sherman, Murray Krahn, International Journal of Radiation OncologyBiologyPhysics Total Androgen SuppressionUrologyRadiation TherapyMedicineVersus Radiation	2005	39
Multimodal therapy in metastatic Ewing's sarcoma: an Intergroup Study. Vietti Tj, Gehan Ea, Nesbit Me, PubMed Surgical OncologyRadiation TherapyMedicineMultimodality TherapyMultimodality	1981	37
Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. long-term results of phase III RTOG study 85-31 M.V. Pilepich, K. Winter, C.A. Lawton, International Journal of Radiation OncologyBiologyPhysics UrologyRadiation MedicineAndrogen Suppression AdjuvantGenitourinary CancerMedicine	2003	33
Phase II Radiation Therapy Oncology Group Study of Hormonal Cytoreduction with Flutamide and Zoladex in Locally Advanced Carcinoma of the Prostate Treated with Definitive Radiotherapy M.V. Pilepich, Madhu J. John, John M. Krall, American Journal of Clinical Oncology	1990	32
Prognostic Value of Survivin in Locally Advanced Prostate Cancer: Study Based on RTOG 8610 Min Zhang, A. Ho, Elizabeth H. Hammond, International Journal of Radiation OncologyBiologyPhysics Prognostic BiomarkersUrologySurgical OncologyGenitourinary CancerRtog 8610	2008	31

Page 1